Allergy Therapeutics update receives broker seal of approval

Allergy Therapeutics reported a “highly encouraging” trading update for the six months to December 2025 with revenues expected at £36.3m versus £34.0m a year earlier (reported growth +7%, ~+3% at constant currency), and Cavendish reiterated a buy rating with a 13p target. The group secured German regulatory approval for Grass MATA MPL (to be marketed as Grassmuno), has begun commercialisation with management targeting potential peak sales of €100m in Germany, and expects sales momentum to accelerate in H2. Balance sheet improvements include £10.1m gross cash, repayment of all outstanding financial indebtedness using £55m of warrant proceeds, and new uncommitted facilities totaling £70m (£50m shareholder loan + £20m). These developments support the broker view that a successful rollout could move the company toward self-sustaining profitability.

Analysis

Market structure: Allergy Therapeutics (AIM:AGY / OTC:AGYTF) and German distributors are clear winners if Grassmuno converts unregistered-product users; success in Germany (peak sales management cites €100m) would materially shift share within Europe’s allergen immunotherapy niche and boost AGY pricing power for follow-up launches. Losers include suppliers of unregistered/self-prepared therapies and incumbent competitors if reimbursement favors the registered product; supply-side risk exists as capacity must scale seasonally to meet concentrated spring pollen demand. Cross-asset: stronger German euro revenue would lift EUR/GBP exposure for AGY, reduce credit stress (lower implied CDS for subordinated lenders), and likely compress equity volatility post-confirmation while raising short-term options activity around H2 uptake updates.

Risk assessment: Key tail risks are regulatory/reimbursement reversals in Germany, slower-than-forecast physician adoption, manufacturing bottlenecks, and the fact that the £70m facility is uncommitted — a financing shortfall could re-lever or dilute equity. Immediate (days) risk is post-update price chop; short-term (weeks–months) hinge on initial commercial traction in H2 FY26 (Jan–Jun 2026); long-term (quarters–years) is whether Grassmuno approaches multi-year €50–100m revenues in Germany. Hidden dependencies include insurer formularies and GP prescribing patterns; catalysts are monthly/quarterly German revenue prints and pharmacy uptake metrics.

Trade implications: For risk-defined exposure, favor small, staged longs and limited-risk option structures to play H2 FY26 rollout: a 2–3% long equity allocation or a 0.5–1% portfolio-sized 9–12 month call spread captures upside while capping downside. Consider a relative-value pair (long AGY vs short 0.5–1% of ALK-B) to isolate German immunotherapy execution versus large-cap incumbents. Avoid levering until two successive quarters of >£5–10m incremental Germany sales or clear drawing of committed financing; use a 35% stop below entry and an initial take-profit near broker target (13p) within 12 months.

Contrarian angles: The market may be underestimating commercialization friction — historical European immunotherapy rollouts often take 2–3 seasons to scale, so H2 acceleration could be muted and the £70m uncommitted facility may prove illusory. Conversely, if early uptake beats expectations (e.g., >€10m in first two quarters), AGY could be significantly underpriced versus 13p target; mispricings exist on both sides. Unintended consequences include payer pushback on pricing and increased regulatory scrutiny of transition from unregistered products, which would quickly reverse gains if adoption stalls.

Key Decisions for Investors

• Establish a staged 2–3% long position in Allergy Therapeutics (AIM:AGY or OTC:AGYTF), scaling over 3 months; use a hard stop at 35% below average entry and plan to take profits if price reaches Cavendish’s 13p target or within 12 months after two consecutive quarters confirming H2 FY26 German revenue acceleration (>£5–10m incremental per quarter).
• Implement a limited-risk options trade sized 0.5–1% of portfolio: buy a 9–12 month at-the-money call and sell a higher strike (call spread) to cap cost; close after confirmed H2 FY26 sales prints or at 12 months to capture commercialization upside while limiting capital at risk.
• Enter a pair trade to isolate execution risk: long AGY 2% vs short ALK-B (Copenhagen: ALK-B) 0.5–1% to hedge macro and thematic exposure; review and rebalance after 6 months or upon definitive German reimbursement/prescribing data.
• Do not increase exposure above 3% until the company reports two sequential quarters of material German sales (threshold: >£5–10m incremental revenue per quarter) and public confirmation that at least £50m of the £70m facilities are drawdown-eligible; if the company fails these tests within 9 months, reduce position to zero.